Abe Sutton, a health policy aide in the first Trump administration, is likely to be named head of the Center for Medicare and ...

At the JPM conference, Pfizer CEO Albert Bourla projected optimism, saying the market was overlooking the pharma company's ...

J&J agreed to buy Intra-Cellular Therapies in a deal worth $14.6 billion, another sign of reentry into neuroscience by large ...

Duke neuroscientist Kafui Dzirasa wants nothing less than to reengineer the brain’s electrical patterns to treat anxiety, ...

This amounts to one of the most significant federal government investments in the behavioral health sector in history. For ...

Cigna and Centene were among a dozen companies that appeared on the initial JPM agenda that have bowed out of the conference.

Asian American populations, particularly when broken down into ethnic groups, have allergy health outcomes that are distinct ...

J&J said it would buy Intra-Cellular Therapies in a deal worth $14.6 billion, another sign of large drugmakers’ reentry into ...

Biogen is looking to augment growth by hunting for biotechs with drugs in mid- and late-stage clinical development.

The CEO of Cytokinetics says the company is not for sale. That doesn't mean it would turn away potential suitors.

Eli Lilly said it would acquire a cancer program from Scorpion Therapeutics in a deal worth up to $2.5 billion, as it broadens its pipeline.

After nearly a decade of machine learning innovations, the FDA has issued its first draft guidance on the use of AI in drug ...